PARIS – Pfizer vaccine is slightly less effective. But it appears to still protect against the more invasive Indian virus that causes COVID-19, according to a study by the French Institute of Pasteur.
Olivier Schwartz, the institute’s director and co-author of the study published on the BioRxiv website, said, “Even with a slight decrease in efficacy, the Pfizer vaccine may be preventable” based on laboratory test results.
The study sampled 28 medical workers in Orleans. Sixteen people received two doses of Pfizer vaccine, while 12 received one dose of AstraZeneca vaccine.
Those who received two doses of Pfizer showed a threefold decrease in their antibodies compared to the Indian variant B.1.617, according to the study, but remained protected.
The study said, “The situation was different with the AstraZeneca vaccine, which stimulated low levels of antibodies, particularly neutralization,” the Indian variant said.
Get The Times of Israel’s Daily Edition by email and never miss our top stories. Sign up for free.
Patients who had been infected with COVID-19 in the past year and who received two doses of Pfizer vaccine still had enough antibodies to be protected against the Indian infection. But antibodies are three to six times less than those in the UK.
The study showed that “this variable .. was given some antibody resistance,” Schwartz said.
Since it first emerged in late 2019 in China, the Covid-19-causing SARS-CoV-2 virus has evolved strains, usually named after the place where it first appeared, including the so-called strain. That South Africa and the United Kingdom
The variables first detected in India appear to be far more passable than the previous variables.
It is now officially recorded in 53 territories, according to the World Health Organization.
In an effort to reduce the spread, France and Germany have adopted again stricter rules for arrivals from affected countries, including the United Kingdom.